Drug intelligence / Profile preview

YPN-008

Development stage: Preclinical
Lead developer: Yungjin Pharm
Modality: Small Molecules

Overview

YPN-008 is an experimental drug candidate being developed by Yungjin Pharmaceutical for the treatment of Parkinson's disease. Currently in the discovery stage, the program is being developed in collaboration with Kanaph Therapeutics and Neurame. As a new chemical entity (NCE) within Yungjin's R&D pipeline, YPN-008 is part of a series of candidates aimed at addressing neurodegenerative and oncological conditions. Detailed information regarding its specific biological target and molecular mechanism of action has not yet been publicly disclosed.

Beyond the preview

Go deeper on YPN-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YPN-008.

Explore the full profile